Brentuximab Vedotin
Brentuximab Vedotin
About this item
Full title
Brentuximab Vedotin
Author / Creator
Publisher
Pittsburgh: Oncology Nursing Society
Journal title
Clinical journal of oncology nursing, 2018-08, Vol.22 (4), p.E103-E114
Language
English
Formats
Publication information
Publisher
Pittsburgh: Oncology Nursing Society
Subjects
More information
Scope and Contents
Contents
Common to both of these malignancies is the expression of CD30, a transmembrane cytokine receptor on malignant cells for both neoplasms (Macalalad et al., 2015). Because of its high expression on malignant cells, CD30 has become a therapeutic target for CDgc-expressing malignancies, including HL and sALCL (Seattle Genetics, 2018). To further suppor...
Alternative Titles
Full title
Brentuximab Vedotin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2080230662
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2080230662
Other Identifiers
ISSN
1092-1095
E-ISSN
1538-067X
DOI
10.1188/18.CJON.E103-E114
How to access this item
Log in as a Library member
